Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells

Cell Cycle

Volumn 3, Issue 3, 2004, Pages 370-377

  Shelton, John G ^a   Steelman, Linda S ^a   White, Edmond R ^a   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Apoptosis; Cell cycle progression; Hematopoietic cells; IGF 1R; Insulin; MEK; PI3K; Signal transduction

Indexed keywords

CASPASE 3; CYTOKINE; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; SOMATOMEDIN C RECEPTOR; AKT1 PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, MOUSE; CASPASE; DNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HEMATOPOIETIC CELL; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; BLOOD CELL; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; BLOOD CELLS; CASPASE 3; CASPASES; CELL CYCLE; CELL LINE; DNA; HUMANS; INTERLEUKIN-3; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 5644252461     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.3.747     Document Type: Article

References (73)

1. Shelton JG, Chang F, Lee JT, Franklin RA, Steelman LS, McCubrey JA. B-Raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell Cycle 2004; In Press.
2. Chang F, Lee JT, Navolanic PM, Franklin RA, McCubrey JA, Steelman JG, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia 2003; 17:590-603.
3. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; In Press.
4. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA, et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: Possible sites for intervention with anti-neoplastic drugs. Leukemia 1999; 13:1109-66.
5. Franklin RA, McCubrey JA. Kinases: Positive and negative regulators of apoptosis. Leukemia 2000; 14:2019-34.
6. White MK, McCubrey JA. Suppression of apoptosis: Role in cell growth and neoplasia. Leukemia 2001; 15:1011-21.
7. McCubrey JA, Steelman LS, Blalock WL, Lee JT, Moye PW, Chang F, et al. Synergistic effects of PI3K/Akt on abrogation of cytokine-dependency induced by oncogenic Raf. Adv Enzyme Regl 2001; 41:289-323.
8. McCubrey JA, Lee JT, Steelman LS, Blalock WL, Moye PW, Chang F, et al. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detection Prevention 2001; 25:375-93.
9. McCubrey JA, Blalock WL, Chang F, Steelman LS, Pohnert SC, Navolanic PM, et al. Signal transduction pathways: Cytokine model. In: M Blagosklonny, ed. Cell Cycle Checkpoints and Cancer. Austin, TX: Landes Bioscience Press, 2001; 17-51.
10. McCubrey JA, May WS, Duronio V, Mufson A. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia 2000; 14:9-21.
11. McCubrey JA, Blalock WL, Saleh O, Pearce M, Burrows C, Steelman LS, et al. Enhanced ability of daniplestim and myelopoietin-1 to suppress apoptosis in human hematopoietic cells. Leukemia 2001; 15:1203-16.
12. Srinivasa SP, Doshi PD. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia 2002; 16:244-53.
13. Lee Jr JT, McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002; 16:486-507.
14. Lee Jr JT, McCubrey JA. Targeting the Raf kinase cascade in cancer therapy - Novel molecular targets and therapeutic strategies. Expert Opin Investig Drugs 2002; 6:659-78.
15. Shelton JG, Moye PW, Steelman LS, Blalock WL, Lee JT, Franklin RA, et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 2003; 17:1765-82.
16. Lee Jr JT, McCubrey JA. BAY 43-9006 Bayer Current Opinion in Investigational Drugs. 2003; 4:757-63.
17. Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene 2001; 20:4353-64.
18. Chang F, Steelman LS, McCubrey JA. Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle 2002; 1:220-6.
19. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17:1263-93.
20. Jucker M, Sudel K, Horn S, Sickel M, Wegner W, Fiedler W, et al. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 2002; 16:894-901.
21. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999; 59:2891-7.
22. Fry MJ. Phosphoinositide 3-kinase signalling in breast cancer: How big a role might it play? Breast Cancer Res 2001; 3:304-12.
23. Lin X, Bohle AS, Dohrmann P, Leuschner I, Schulz A, Kremer B, et al. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 2001; 386:293-301.
24. Krasilnikov M, Adler V, Fuchs SY, Dong Z, Haimovitz-Friedman A, Herlyn M, et al. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 1999; 24:64-9.
25. Martinez-Lorenzo MJ, Anel A, Monleon I, Sierra JJ, Pineiro A, Naval J, et al. Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia. Int J Biochem Cell Biol 2000; 32:435-45.
26. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14:381-95.
27. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29-39.
28. Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 1998; 143:1375-83.
29. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273:13375-8.
30. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998; 95:13513-8.
31. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-7.
32. Choudhury GG, Karamitsos C, Hernandez J, Gentilini A, Bardgette J, Abbound HE. 1997. PI-3-kinase and MAPK regulate mesangial cell proliferation and migration in response to PDGF. Am J Physiol 1997; 273:F931-8.
33. 1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499-511.
34. Gille H, Downward J. Multiple ras effector pathways contribute to G1 cell cycle progressio. J Biol Chem 1999; 274:22033-40.
35. Kip1. Nature 2000; 404:782-7.
36. Muise-Helmericks RC, Grimers HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998; 273:29864-72.
37. KiP1 gene expression. J Biol Chem 2002; 276:35636-43.
38. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. P21 is a universal inhibitor of cyclin kinases. Nature 1993; 366:701-4.
39. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995; 6:387-400.
40. Sherr CJ, Roberts MJ. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-12.
41. Rank KB, Evans DB, Sharma SK. The N-terminal domains of cycllin-dependent kinase inhibitory proteins block the phosphorylation of cdk2/cyclin E by the CDK-activating kinase. Biochem Biophys Res Commun 2000; 271:469-73.
42. Shimizu T, Takahashi N, Tachibana K, Takeda K. Complex regulation of CDK2 and G1 arrest during neuronal differentiation of human prostatic cancer TSU-Prl cells by staurosporine. Anticancer Res 2001; 21:893-8.
43. Lawlor MA, Rotwein P. Insulin-like growth factor-mediated muscle cell survival: Central roles for Akt and cyclin-dependent kinase inhibitor p21. Mol Cell Biol 2000; 23:8983-95.
44. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87:629-38.
45. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996 56:1851-4.
46. Lau QC, Brusselbach S, Muller R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene 1998; 16:1899-902.
47. Salomoni P, Wasik MA, Riedel RF, Reiss K, Choi JK, Skorski T, et al. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med 1998; 187:1995-2007.
48. Majewski M, Nieborowska-Skorska M, Salomoni P, Slupianek A, Reiss K, Trotta R, et al. Calabretta B, Skorski T. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res 1999; 59:2815-9.
49. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999; 19:7203-15.
50. McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA, et al. Differential abilities of activated Raf oncoproteins to abrogate cytokine-dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998; 12:1903-29.
51. McCubrey JA, Steelman LS, Moye PW, Hoyle PE, Weinstein-Oppenheimer C, Chang F, et al. Effects of deregulated Raf and MEK1 expression on the cytokine-dependency of hematopoietic cells. Adv Enzyme Regl 2000; 40:305-37.
52. Moye PW, Blalock WL, Hoyle PE, Chang F, Franklin RA, Weinstein- Oppenheimer C, et al. Synergy between Raf and BCL2 in abrogating the cytokine-dependency of hematopoietic cells. Leukemia 2000; 14:1060-79.
53. Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M, et al. Differential abilities of the Raf family of protein of kinases to abrogate cytokine-dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 2000; 14:642-56.
54. Waf1 and p53 requires c-raf-1. Cancer Res 1995; 55:4623-6.
55. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI3K and PKB. Nature 1997; 385:544-8.
56. Basu S, Bayoumy S, Zhang Y, Lozano J, Kolesnick R. BAD enables ceramide to signal apoptosis via Ras and Raf-1. J Biol Chem 1998; 273:30419-26.
57. von Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, Rapp UR, et al. Apoptosis suppression by Raf-1 and MEK1 requires MEK and phosphatidylinositol 3-kinase dependent signals. Mol Cell Biol 2001; 21:2324-36.
58. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91:231-241.
59. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. P70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule Bad. Proc Natl Acad Sci USA 2001; 98:9666-70.
60. Virdee K, Parone PA, Tolkovsky AM. Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival. Curr Biol 2000; 10:1151-4
61. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269:5241-8.
62. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 1993; 296:297-301.
63. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996; 58:373-95.
64. Choudhury GG, Kim YS, Simon M, Wozney J, Harris S, Choudhury GN, et al. Bone morphogenetic protein 2 inhibits paltelet-derived growth factor-induced c-fos gene transcription and DNA synthesis in mesangial cells. Involvement of mitogen-activated protein kinase. J Biol Chem 1999; 274:10897-902.
65. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857-868.
66. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas SH, Lam EWF, et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27Kip1. Mol Cell Biol 2000; 20:9138-48.
67. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996; 58:373-95.
68. Cip1. Mol Cell Biol 1997; 17:5598-611.
69. Lloyd AC, Obermuller F, Staddon S, Barth CF, McMahon M, Land H. Cooperating oncogenes converge to regulate cyclin/Cdk complexes. Genes Dev 1997; 11:663-677.
70. Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H, et al. A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. Oncogene 2000; 19:526-36.
71. Blalock WL, Moye PW, Chang F, Pearce M, Steelman LS, McMahon M, et al. Combined effects of aberrant MEK1 activity and BCL-2 overexpression on relieving the cytokine-dependency of human and murine hematopoietic cells. Leukemia 2000; 14:1080-96.
72. Blalock WL, Pearce M, Chang F, Lee J, Pohnert SC, Burrows C, et al. Effects of inducible MEK1 activation on the cytokine-dependency of lymphoid cells. Leukemia 2001; 15:794-807.
73. McCubrey JA, Steelman LS, Mayo MW, Algate PA, Dellow RA, Kaleko M. Growth promoting effects of insulin-like growth factor-1 on hematopoietic cells: Overexpression of introduced IGF-1 receptor abrogates IL-3-dependency of murine factor dependent cells by a ligand-dependent mechanism. Blood 1991; 78:921-9.